Contribution of bradykinin B2 receptors to the inhibition by valsartan of systemic and renal effects of exogenous angiotensin II in salt-repleted humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 911-916

  Biggi, Almerina ^a   Musiari, Luisa ^a   Iori, Matteo ^a   De Iaco, Giuseppe ^a   Magnani, Giulia ^a   Pelloni, Irene ^a   Pinelli, Silvana ^a   Pelà, Giovanna M ^a   Novarini, Almerico ^a   Cabassi, Aderville ^a   Montanari, Alberto ^a  

^a UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BRADYKININ B2 RECEPTOR; ICATIBANT; PLACEBO; VALSARTAN; 4 AMINOHIPPURIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; INULIN; SODIUM; TETRAZOLE DERIVATIVE; VALINE;

4 AMINOHIPPURIC ACID CLEARANCE; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; INULIN CLEARANCE; KIDNEY BLOOD FLOW; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; SODIUM RESTRICTION; SODIUM URINE LEVEL; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; DRUG EFFECTS; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; URINE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONISTS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INDICATORS AND REAGENTS; INULIN; KIDNEY; MALE; P-AMINOHIPPURIC ACID; RECEPTOR, BRADYKININ B2; RENAL CIRCULATION; SODIUM; TETRAZOLES; VALINE;

EID: 77956249197     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166942     Document Type: Article

References (39)

1. Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, and Camisasca RP (2004) Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15:3126-3133.
2. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, and Danser AH (2004) Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 109:2296-2301.
3. Biggi A, Carra N, Cabassi A, Barilli AL, Musiari L, Iori M, De Iaco G, Azzarone M, Novarini A, and Montanari A (2007) Impaired renal haemodynamic response to L-arginine in essential hypertension: role of buffering anion and tubuloglomerular feedback. J Hypertens 25:679-688.
4. Brillante DG, O'Sullivan AJ, Johnstone MT, and Howes LG (2008) Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance. Diabetes Obes Metab 10:143-150.
5. Brown NJ, Gainer JV, Murphey LJ, and Vaughan DE (2000) Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase- independent pathway. Circulation 102:2190-2196.
6. Burnier M, Roch-Ramel F, and Brunner HR (1996) Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 49:1787-1790.
7. Carey RM (2005) Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 45: 840-844.
8. Carey RM and Padia SH (2008) Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 19:84-87.
9. Carretero OA and Scicli AG (1995) The kallikrein-kinin system as a regulator of cardiovascular and renal function, in Hypertension, Pathophysiology, Diagnosis, and Management (Laragh JH and Brenner BM, eds), 2nd ed, pp 983-999, Raven Press Ltd, New York.
10. Cockcroft JR, Chowienczyk PJ, Brett SE, Bender N, and Ritter JM (1994) Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol 38:317-321.
11. Cruden NL, Witherow FN, Webb DJ, Fox KA, and Newby DE (2004) Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin- converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol 24:1043-1048.
12. Davie AP, Dargie HJ, and McMurray JJ (1999) Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 100: 268-273.
13. Gainer JV, Morrow JD, Loveland A, King DJ, and Brown NJ (1998) Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339:1285-1292.
14. Gandhi SK, Ryder DH, and Brown NJ (1996) Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 28:961-966.
15. Hornig B, Kohler C, and Drexler H (1997) Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95: 1115-1118.
16. Hornig B, Kohler C, Schlink D, Tatge H, and Drexler H (2003) AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism. Hypertension 41:1092-1095.
17. Jones ES, Vinh A, McCarthy CA, Gaspari TA, and Widdop RE (2008) AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 120:292-316.
18. Latif F, Tandon S, Obeleniene R, Hankins SR, Berlowitz MS, Ennezat PV, and Le Jemtel TH (2001) Angiotensin type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects. J Card Fail 7:265-268.
19. LeFebvre J, Shintani A, Gebretsadik T, Petro JR, Murphey LJ, and Brown NJ (2007) Bradykinin B2 receptor does not contribute to blood pressure lowering during AT1 receptor blockade. J Pharmacol Exp Ther 320:1261-1267.
20. Madeddu P, Anania V, Parpaglia PP, Demontis MP, Varoni MV, Pisanu G, Troffa C, Tonolo G, and Glorioso N (1992) Effects of Hoe 140, a bradykinin B2-receptor antagonist, on renal function in conscious normotensive rats. Br J Pharmacol 106:380-386.
21. Madeddu P, Emanueli C, and El-Dahr S (2007) Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodelling. Nat Clin Pract Nephrol 3:208-221.
22. Maillard MP, Würzner G, Nussberger J, Centeno C, Burnier M, and Brunner HR (2002) Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 71:68-76.
23. Montanari A, Biggi A, Carra N, Ziliotti M, Fasoli E, Musiari L, Perinotto P, and Novarini A (2003) Endothelin-A receptors mediate renal hemodynamic effects of exogenous angiotensin II in humans. Hypertension 42:825-830.
24. Morgan JM, Palmisano M, Piraino A, Hirschhorn W, Spencer S, Prasad PP, Ortiz M, and Lloyd P (1997) The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Clin Pharmacol Ther 61:35-44.
25. Murphey LJ, Eccles WK, Williams GH, and Brown NJ (2004) Loss of sodium modulation of plasma kinins in human hypertension. J Pharmacol Exp Ther 308:1046-1052.
26. Murphey LJ, Kumar S, and Brown NJ (2000) Endogenous bradykinin and the renin and pressor responses to furosemide in humans. J Pharmacol Exp Ther 295:644-648.
27. Omoro SA, Majid DS, El Dahr SS, and Navar LG (2000) Roles of AngII and bradykinin in the renal regional blood flow responses to ACE inibition in sodium-depleted dogs. Am J Physiol Renal Physiol 279:F289-F293.
28. Price DA, De'Oliveira JM, Fisher ND, and Hollenberg NK (1997) Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 30:240-246.
29. Savoia C, Touyz RM, Volpe M, and Schiffrin EL (2007) Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 49:341-346.
30. Schmitt F, Martinez F, Brillet G, Nguyen-Khoa T, Brouard R, Sissmann J, Lacour B, and Grunfeld JP (1998) Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects. J Cardiovasc Pharmacol 31:314-321.
31. Siragy HM (2010) The angiotensin II type 2 receptor and the kidney. J Renin- Angiotensin-Aldosterone Syst 11:33-36.
32. Siragy HM, Ibrahim MM, Jaffa AA, Mayfield R, and Margolius HS (1994) Rat renal interstitial bradykinin, prostaglandin E2, and cyclic guanosine 3′,5′-monophosphate. Effects of altered sodium intake. Hypertension 23:1068-1070.
33. Siragy HM, Jaffa AA, Margolius HS, and Carey RM (1996) Renin-angiotensin system modulates renal bradykinin production. Am J Physiol Regul Integr Comp Physiol 271:R1090-R1095.
34. Sivritas SH, Ploth DW, and Fitzgibbon WR (2008) Blockade of renal medullary bradykinin B2 receptors increases tubular sodium reabsorption in rats fed a normal salt diet. Am J Physiol Renal Physiol 295:F811-F817.
35. Squire IB, O'Kane KP, Anderson N, and Reid JL (2000) Bradykinin B2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 36:132-136.
36. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, et al. (1999) Angiotensin II type 2 overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104:925-935.
37. Visser FW, Boonstra AH, Titia Lely A, Boomsma F, and Navis G (2008) Renal response to angiotensin II is blunted in sodium-sensitive normotensive men. Am J Hypertens 21:323-328.
38. Weir MR (2007) ) Effects of renin-angiotensin system inhibition end-organ protection: can we do better? Clin Ther 29:1803-1824.
39. Yayama K and Okamoto H (2008) Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 8:312-318.